Half-year Report 2023

Financial ReportInterim consolidated statement of changes in equity

Interim consolidated statement of changes in equity

1 January - 30 June (unaudited)
Attributable to shareholders of PolyPeptide Group AG:


kEUR	Share capital	Share premium	Translation reserve	Treasury shares	Other capital reserves	Retained earnings	Total

Balance as at 1 January 2023	302	203,129	14,119	-13,609	3,590	214,146	421,677

Result for the period						-34,266	-34,266
Remeasurement gain / (loss) on defined benefit plans, net of tax						2,231	2,231
Currency exchange differences			-5,720				-5,720
Total comprehensive income	–	–	-5,720	–	–	-32,035	-37,755

Purchase of own shares							–
Dividends paid							–
Share-based payment					393		393
Transfer of own shares				1,327	-1,327		–
Total transactions with owners	–	–	–	1,327	-934	–	393
Balance as at 30 June 2023	302	203,129	8,399	-12,282	2,656	182,111	384,315

Interim consolidated statement of changes in equity (continued)

1 January - 30 June (unaudited)
Attributable to shareholders of PolyPeptide Group AG:


kEUR	Share capital	Share premium	Translation reserve	Treasury shares	Other capital reserves	Retained earnings	Total

Balance as at 1 January 2022	302	212,800	9,285	-1,187	3,946	196,028	421,174

Result for the period						10,247	10,247
Remeasurement gain / (loss) on defined benefit plans, net of tax						7,690	7,690
Currency exchange differences			8,840				8,840
Total comprehensive income	–	–	8,840	–	–	17,937	26,777

Purchase of own shares				-11,962			-11,962
Dividends paid		-9,671					-9,671
Share-based payment					991		991
Transfer of own shares				188	-188		–
Total transactions with owners	–	-9,671	–	-11,774	803	–	-20,642
Balance as at 30 June 2022	302	203,129	18,125	-12,961	4,749	213,965	427,309

Interim consolidated statement of financial position

Interim consolidated statement of cash flow